← Back to all signals
RESEARCH PAPER ANALYSIS

Subjective cognitive concerns and global metacognitive bias in prodromal Parkinson's and Parkinson's disease without cognitive impairment.

This study shows that negative global metacognitive bias—driven by depression and anxiety—underlies subjective cognitive complaints in prodromal PD and PD without objective impairment.

PMID41989436
JournalNeuropsychology
Publication Date2026-04-16
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This study shows that negative global metacognitive bias—driven by depression and anxiety—underlies subjective cognitive complaints in prodromal PD and PD without objective impairment.

WHY IT MATTERS

Research significance

While not revealing molecular targets, this identifies modifiable affective contributors and measurement considerations that could inform symptomatic treatments, patient selection, and outcome measures in PD trials.

ABSTRACT

Source abstract

OBJECTIVE: Subjective cognitive decline is common in persons with Parkinson's disease (PwPD) and prodromal PD (proPD) and predicts objective cognitive decline. Subjective concerns may reflect enhanced sensitivity to cognitive changes or negative global metacognitive biases (general underconfidence, not task specific) related to depression or anxiety. We evaluated the presence and predictors of metacognitive awareness, the self-assessment of one's cognitive abilities, in PwPD and proPD. METHOD: Data from 468 PwPD, 817 proPD, and 75 healthy control adults were drawn from the Parkinson's Progressive Markers Initiative database. Measures included subjective- and objective-cognitive composites. We assessed metacognitive sensitivity (the relation between subjective and objective cognition) and the relation between metacognitive bias (subjective minus objective cognition) and depression, anxiety, demographics, and PD-related variables. Significant associations were included in linear regression models separately for PwPD and proPD. To assess effect consistency, we examined baseline versus Time 2 difference scores in a subsample who had the same measures 12 months later. RESULTS: ProPD (ρ = .13), but not PwPD (ρ = .08), showed significant metacognitive sensitivity. More negative metacognitive bias was predicted by age, education, depression, and trait anxiety in PwPD (R² = .17) and proPD (R² = .24). The relation between anxiety and negative metacognitive bias was consistent over a 12-month period for PwPD (ρ = -.18; R² = .05). CONCLUSIONS: Negative metacognitive bias, predicted by depression and anxiety, may underlie subjective cognitive concerns in PwPD and proPD, with implications for treatment. These findings support using global approaches to metacognitive awareness, which are likely more accurate measures of daily cognitive awareness than are task-specific measures. (PsycInfo Database Record (c) 2026 APA, all rights reserved).

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic